Jos Beijnen
Impact in
- Oncology top 0.01%
- Drug Transport and Resistance Mechanisms
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- Pharmacology top 0.01%
- Pharmacogenetics and Drug Metabolism
Papers in
- Oncology 632
- Drug Transport and Resistance Mechanisms 224
- Cancer Treatment and Pharmacology 191
- Colorectal Cancer Treatments and Studies 97
- Pharmacology 166
- Pharmacogenetics and Drug Metabolism 150
- Co-authors
- Jan H.M. Schellens (251 shared papers)Hilde Rosing (251 shared papers)Alwin D. R. Huitema (251 shared papers)Olaf van Tellingen (138 shared papers)Alfred H. Schinkel (157 shared papers)Piet Borst (19 shared papers)Rolf W. Sparidans (136 shared papers)Els Wagenaar (45 shared papers)
- Journals
- Journal of Chromatography B (90 papers)Journal of Pharmaceutical and Biomedical Analysis (74 papers)Cancer Chemotherapy and Pharmacology (71 papers)Investigational New Drugs (49 papers)International Journal of Pharmaceutics (47 papers)
- Partner nations
- NetherlandsUnited StatesUnited Kingdom
In The Last Decade
Jos Beijnen
1.5k papers receiving 62.2k citations
Jos Beijnen's Hit Papers
Peers
Comparison fields: 5 of 189
- Oncology 26.8k
- Pharmacology 5.7k
- Virology 2.0k
- Pharmaceutical Science 2.4k
- Pediatrics, Perinatology and Child Health 6.8k
Countries citing papers authored by Jos Beijnen
This map shows the geographic impact of Jos Beijnen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jos Beijnen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jos Beijnen more than expected).
Fields of papers citing papers by Jos Beijnen
This network shows the impact of papers produced by Jos Beijnen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jos Beijnen. The network helps show where Jos Beijnen may publish in the future.
Co-authors
The 25 scholars most cited alongside Jos Beijnen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 1.5k papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs Hit paper breakdown → | 1994 | 1963 |
| 2 | Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine Hit paper breakdown → | 1997 | 788 |
| 3 | A Phase I and Pharmacological Study with Imidazolium- trans- DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent Hit paper breakdown → | 2004 | 784 |
| 4 | The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria Hit paper breakdown → | 2002 | 708 |
| 5 | Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis Hit paper breakdown → | 2012 | 632 |
| 6 | Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies Hit paper breakdown → | 2010 | 603 |
| 7 | 2005 | 504 | |
| 8 | 2011 | 470 | |
| 9 | A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. | 2002 | 454 |
| 10 | Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors Hit paper breakdown → | 2019 | 450 |
| 11 | 1995 | 447 | |
| 12 | 2003 | 443 | |
| 13 | 2000 | 418 | |
| 14 | Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma Hit paper breakdown → | 2022 | 399 |
| 15 | 2002 | 390 | |
| 16 | 1997 | 382 | |
| 17 | 2005 | 363 | |
| 18 | Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy Hit paper breakdown → | 2014 | 338 |
| 19 | 2018 | 318 | |
| 20 | 2015 | 304 |
About Jos Beijnen
Jos Beijnen is a scholar working on Oncology, Pharmacology, Molecular Biology, Infectious Diseases and Pediatrics, Perinatology and Child Health, having authored 1.5k papers that have together received 64.5k indexed citations. Recurring topics across this work include Drug Transport and Resistance Mechanisms (224 papers), Cancer Treatment and Pharmacology (191 papers), Cancer therapeutics and mechanisms (173 papers), Pharmacogenetics and Drug Metabolism (150 papers), HIV/AIDS drug development and treatment (130 papers), Pharmacological Effects and Toxicity Studies (114 papers), Colorectal Cancer Treatments and Studies (97 papers) and Chemotherapy-induced organ toxicity mitigation (74 papers). The work is most often cited by research in Oncology (26.8k citations), Pharmacology (5.7k citations), Virology (2.0k citations), Pharmaceutical Science (2.4k citations) and Pediatrics, Perinatology and Child Health (6.8k citations). Jos Beijnen has collaborated with scholars based in Netherlands, United States and United Kingdom. Frequent co-authors include Jan H.M. Schellens, Hilde Rosing, Alwin D. R. Huitema, Olaf van Tellingen, Alfred H. Schinkel, Piet Borst, Rolf W. Sparidans, Els Wagenaar, Wim W. ten Bokkel Huinink and Dick Pluim. Their work appears in journals such as Journal of Chromatography B, Journal of Pharmaceutical and Biomedical Analysis, Cancer Chemotherapy and Pharmacology, Investigational New Drugs and International Journal of Pharmaceutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.